Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
Medpace Stock Performance
Shares of NASDAQ:MEDP opened at $182.30 on Friday. The stock has a market cap of $5.65 billion, a PE ratio of 31.65 and a beta of 1.43. The business has a fifty day moving average of $154.24 and a two-hundred day moving average of $152.79. Medpace has a 52-week low of $126.94 and a 52-week high of $231.00.
Medpace (NASDAQ:MEDP - Get Rating) last released its quarterly earnings results on Monday, July 25th. The company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.13. Medpace had a return on equity of 30.56% and a net margin of 16.27%. The business had revenue of $351.21 million during the quarter, compared to analysts' expectations of $344.01 million. During the same period in the previous year, the business posted $1.06 earnings per share. The firm's revenue for the quarter was up 26.2% compared to the same quarter last year. Analysts predict that Medpace will post 6.16 earnings per share for the current year.
Wall Street Analysts Forecast Growth
MEDP has been the topic of several recent research reports. StockNews.com raised shares of Medpace from a "hold" rating to a "buy" rating in a research report on Thursday, July 28th. Guggenheim began coverage on shares of Medpace in a research note on Monday, May 23rd. They issued a "neutral" rating on the stock.
Insider Activity at Medpace
In other Medpace news, CEO August J. Troendle purchased 8,330 shares of the business's stock in a transaction that occurred on Monday, July 18th. The stock was acquired at an average cost of $145.00 per share, with a total value of $1,207,850.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,513,639 shares of the company's stock, valued at approximately $799,477,655. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO August J. Troendle acquired 8,330 shares of the company's stock in a transaction on Monday, July 18th. The stock was purchased at an average cost of $145.00 per share, with a total value of $1,207,850.00. Following the acquisition, the chief executive officer now owns 5,513,639 shares of the company's stock, valued at approximately $799,477,655. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO August J. Troendle acquired 22,290 shares of the company's stock in a transaction on Thursday, July 14th. The shares were purchased at an average cost of $144.59 per share, with a total value of $3,222,911.10. Following the completion of the acquisition, the chief executive officer now directly owns 5,505,309 shares in the company, valued at approximately $796,012,628.31. The disclosure for this purchase can be found here. 20.60% of the stock is currently owned by company insiders.